{"prompt": "['low haptoglobin with schistocytes on peripheral blood smears. The patient was', 'diagnosed with TMA and recovered without plasmapheresis or hemodialysis after 9-18', 'days. The patient restarted treatment with emicizumab approximately 10 days-after', 'resolution of the serious adverse event without recurrence of TMA.', 'The third patient presented at the hospital complaining of rectal bleeding, postural dizziness, and', 'exertional dyspnea. Of note,', 'Multiple doses of rFVIIa were administered and various interventions', '(hemostatic powder application, absorbable hemostat packing, and embolization of rectal arteries)', 'were used in an attempt to control bleeding. Despite these measures, the patient continued to have', \"rectal hemorrhage. The patient's bypassing agent treatment was then changed to aPCC and\", 'temporary cessation of bleeding was achieved. Subsequently, the patient developed a serious', 'adverse event of TMA following concomitant bypassing agent treatment. Emicizumab', 'prophylaxis and aPCC were discontinued and therapeutic plasma exchange with albumin was', \"provided. Three days later, investigators assessed the patient's TMA to be improving based on\", 'laboratory assessments (LDH and platelet count). However, the patient experienced recurrent', 'rectal hemorrhage. Surgery and arterial embolization were no longer deemed to be feasible and the', 'patient was placed on comfort care before passing away the same day. The investigator assessed', 'the patient death as related to the serious adverse event of rectal hemorrhage and unrelated to', 'emicizumab, and the TMA as related to emicizumab and aPCC. For more details please refer to', \"the Emicizumab Investigator's Brochure.\", 'These events should be reported as adverse events of special interest (see Section 5.2.3),', 'and also as serious adverse events if it meets criteria as described in Section 5.2.2. TMA', 'events should be reported as serious adverse events or adverse events of special interest', 'as described in Sections 5.2.2 and 5.2.3. respectively.-HCPs should educate', 'patients/caregivers to recognize signs and symptoms of potential TMA (i.e., confusion,', 'weakness, swelling of arms and legs, yellowing of skin and eyes, vague abdominal or back', 'pain, nausea, vomiting, or decreased urination, etc.) and ensure that they understand the', 'importance of seeking appropriate medical attention. Patients and/or caregivers will also', 'receive two alert cards to remind them of this information and these instructions should TMA', 'be suspected.', '5.1.1.4', 'Hypersensitivity', 'Since emicizumab is a biological product, acute systemic hypersensitivity reactions,', 'including anaphylactic/anaphylactoid reactions, may occur. In Study ACE001JP, no severe', 'hypersensitivity reactions or anaphylactic/anaphylactoid reactions have been observed.', 'These events should be reported as serious adverse events or adverse events of special', 'interest as described in Sections 5.2.2 and 5.2.3, respectively.', 'HCPs administering emicizumab the study modication in the clinic must be trained in the', 'appropriate administration procedures; be able to recognize the signs and symptoms', 'associated with potential hypersensitivity, anaphylactic, and anaphylactoid reactions; and', \"should be familiar with Sampson's criteria for defining anaphylaxis (Sampson et al. 2006;\", 'see Appendix 4). HCPs should also instruct patients how to recognize the signs and', 'symptoms of hypersensitivity, anaphylactic, and anaphylactoid reactions and to contact an', 'Emicizumab - F. Hoffmann-La Roche Ltd', '38 / Protocol MO39129, Version 3']['HCP or seek emergency care in case of any such occurrence. Patients/caregivers will also', 'receive two alert cards to remind them of this information should any of these reactions', 'occur.', '5.1.2', 'Management of Patients Who Experience Specific Adverse Events', 'Table 1', 'Guidelines for Management of Patients Who Experience Specific', 'Adverse Events', 'Event', 'Action to Be Taken', 'Hypercoagulation and risk', 'Investigators should be vigilant for patients who exhibit', 'of thrombosis', 'signs/symptoms consistent with thrombotic disease and should', 'immediately begin work up and treatment as per local', 'guidelines.', 'If a patient has a thromboembolic event, further administration', 'of emicizumab study drug should be interrupted. The investigator', 'must contact the Medical Monitor to assess if the clinical benefit', 'clearly outweighs the risk to determine if the patient should', \"resume taking emicizumab and discuss the patient's continued\", 'study participation.', 'Please see Sections 4.4.1 and 4.5.6.9 for guidance on the', 'management of breakthrough bleeds, including required', 'laboratory monitoring.', 'TMA', 'Investigators should be vigilant for patients who exhibit', 'signs/symptoms consistent with TMA and immediately begin', 'work-up and treatment, as per local guidelines.', 'If a patient has a TMA event, further administration of', 'emicizumab study drug should be interrupted. The decision to', 'resume taking emicizumab after a TMA event must be', 'discussed with and approved by the Medical Monitor.', 'Please see Sections 4.4.1 and 4.5.6.9 for guidance on the', 'management of breakthrough bleeds, including required', 'laboratory monitoring.', 'ADA=anti-drug antibody; TMA=thrombotic microangiopathy', '5.1.3', 'Interpretation of Coagulation Assays for Patients Receiving Emicizumab', 'Emicizumab interacts with standard laboratory assays used in the management of patients', 'with hemophilia A (see Table 11). In one-stage assays, emicizumab is associated with a', 'supra-physiologically short time to clot formation and thus normalization of aPTT at', 'sub-therapeutic levels-and an overestimation of true FVIII activity. Emicizumab is not', 'recognized or neutralized by FVIII inhibitors, and therefore FVIII inhibitors cannot be', 'detected in the presence of emicizumab by functional tests such as Bethesda or Nijmegen-', 'Bethesda assays, which use a one-stage clotting-based readout. Emicizumab activity cannot', 'be detected by chromogenic assays using purified bovine coagulation proteins, thus', 'chromogenic Bethesda assays using bovine proteins can be used to measure FVIII inhibitor titer in the', 'Emicizumab - F. Hoffmann-La Roche Ltd', '39 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}